Noxopharm Share Price and Company Fundamentals
Last traded: Today at 5:10 AM
Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions. The company also develops orphan drug designations to treat less common disease; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types. The company was incorporated in 2015 and is based in Glenhaven, Australia.
Key Metrics
PE ratio
-
PB ratio
32.50
Dividend yield
-
Beta
-0.20
Market cap
$19.00M
Enterprise value
$19.92M
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Website | https://www.noxopharm.com |
| Mailing address | 60 Linksley Avenue Glenhaven NSW 2156 Australia |
| Phone / Fax | 61 2 9144 2223 / |
Dividends
More: Noxopharm Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Noxopharm paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.NOX dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Noxopharm.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Dr. Gisela Mautner | CEO, Executive MD & Director | ||
| Mr. Shawn Van Boheemen FCPA, J.P. | Chief Financial Officer | ||
| Ms. Jeanette Bell Ph.D. | Chief Operating Officer | ||
| Dr. Olivier Laczka B.S., M.Sc., Ph.D. | Chief Scientific Officer of Inflammation | ||
| Mr. David James Franks BEc, C.A., F Fin, J.P. | Company Secretary | 55 |
Profitability and management effectiveness
Profit margin
-173.15%
Operating margin
-187.85%
Return on assets
-59.24%
Return on equity
-157.93%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Noxopharm is 19.00M and its enterprise value is 19.92M. The enterprise value to revenue ratio of NOX is 7.06. The enterprise value to EBITDA ratio of NOX is -3.70.
Companies similar to Noxopharm (NOX)
Noxopharm (ASX:NOX) Frequently Asked Questions
1. What is Noxopharm's Stock Symbol?
Noxopharm trades on ASX under the ticker symbol "NOX".
2. What is Noxopharm's stock price today?
One share of NOX stock can currently be purchased for approximately $0.065.
3. How can I contact Noxopharm?
Noxopharm's mailing address is 60 Linksley Avenue Glenhaven NSW 2156 Australia. The company can be reached via phone at 61 2 9144 2223.
4. What is Noxopharm's official website?
The official website of Noxopharm is https://www.noxopharm.com.